IP Library Granted Patent US 6,869,797
Granted Patent B2
US 6,869,797 · App. 10/611,806 · Granted Mar 22, 2005

Method for more efficient electroporation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,869,797
App. No.
10/611,806
Granted
Mar 22, 2005
Kind
B2
Abstract

This invention provides improved electroporation methods for transferring nucleic acids of interest into host cells, wherein the host cells are (1) suspended in a substantially non-ionic solution comprising at least one sugar or sugar derivative, (2) mixed with the nucleic acids of interest, and (3) electrically treated. Also, this invention provides for kits used in the method for transferring nucleic acids into host cells.

Claims (44)

1. A method for transferring nucleic acids of interest into host cells comprising:

(a) suspending the host cells in a substantially non-ionic solution comprising at least one sugar or sugar derivative;

(b) freezing and thawing the host cells either before or after the suspending;

(c) mixing the host cells with the nucleic acids of interest; and

(d) subjecting the host cells to an electrical treatment, thereby permitting the transfer of the nucleic acids of interest into the host cells.

2. The method of claim 1 , wherein the non-ionic solution further comprises glycerol or dimethyl sulfoxide.

3. The method of claim 1 , wherein the host cells are gram-negative bacterial cells.

4. The method of claim 3 , wherein the gram-negative bacterial cells are E. coli.

5. The method of claim 1 , further comprising culturing the transformed cells in a selected media capable of promoting their growth.

6. The method according to claim 1 , wherein the concentration of the sugar or sugar derivative is in the range of about 0.1% to about 5%.

7. The method according to claim 1 , wherein the sugar or sugar derivative is sorbitol in a concentration range of about 2.0% to about 2.5%.

8. The method according to claim 1 , wherein the sugar or sugar derivative is an aldose.

9. The method according to claim 8 , wherein the aldose is selected from monosaccharides, disaccharides, trisaccharides, and oligosaccharides.

10. The method according to claim 1 , wherein the sugar or sugar derivative is an aldose alcohol.

11. The method according to claim 10 , wherein the aldose alcohol is selected from erythritol, sorbitol, and mannitol.

12. The method according to claim 1 , wherein the sugar or sugar derivative is a ketose.

13. The method of according to claim 12 , wherein the ketose is selected from dihydroxyacetone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, and tagatose.

14. The method according to claim 1 , wherein the sugar or sugar derivative is an aminosugar.

15. The method according to claim 14 , wherein the aminosugar is at least one aminosugar selected from glucosamine, galactosamine, N-acetylglucosamine, N-acetylgalactosamine, muramic acid, N-acetyl muramic acid, and sialic acid.

16. The method according to claim 1 , wherein the sugar or sugar derivative is a glycoside.

17. The method according to claim 16 , wherein the glycoside is selected from glucopyranose and methyl-glucopyranose.

18. The method according to claim 1 , wherein the sugar or sugar derivative is a lactone.

19. The method according to claim 18 , wherein the lactone is gluconolactone.

20. The method according to claim 1 , wherein the non-ionic solution comprises a mixture of sugars, sugar derivatives, or both sugars and sugar derivatives.

21. A kit comprising transformation competent cells suspended in a substantially non-ionic solution comprising (a) at least one sugar or sugar derivative, and (b) a cryopreservative selected from glycerol and dimethyl sulfoxide.

22. The kit according to claim 21 , wherein the transformation competent cells are gram-negative bacterial cells.

23. The kit according to claim 22 , wherein the gram-negative bacterial cells are E. coli.

24. The kit according to claim 21 , wherein the concentration of the sugar or sugar derivative is in the range of about 0.1% to about 5%.

25. The kit according to claim 21 , wherein the sugar or sugar derivative is sorbitol in a concentration range of about 2.0% to about 2.5%.

26. The kit according to claim 21 , wherein the sugar or sugar derivative is an aldose.

27. The kit according to claim 26 , wherein the aldose is selected from monosaccharides, disaccharides, trisaccharides, and oligosaccharides.

28. The kit according to claim 21 , wherein the sugar or sugar derivative is an aldose alcohol.

29. The kit according to claim 28 , wherein the aldose alcohol is selected from erythritol, sorbitol, and mannitol.

30. The kit according to claim 21 , wherein the sugar or sugar derivative is a ketose.

31. The kit according to claim 30 , wherein the ketose is selected from dihydroxyacetone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, and tagatose.

32. The kit according to claim 21 , wherein the sugar or sugar derivative is an aminosugar.

33. The kit according to claim 32 , wherein the aminosugar is at least one aminosugar selected from glucosamine, galactosamine, N-acetylglucosamine, N-acetylgalactosamine, muramic acid, N-acetyl muramic acid, and sialic acid.

34. The kit according to claim 21 , wherein the sugar or sugar derivative is a glycoside.

35. The kit according to claim 34 , wherein the glycoside is selected from glucopyranose and methyl-glucopyranose.

36. The kit according to claim 21 , wherein the sugar or sugar derivative is a lactone.

37. The kit according to claim 36 , wherein the lactone is gluconolactone.

38. The kit according to claim 21 , wherein the non-ionic solution comprises a mixture of sugars, sugar derivatives, or both sugars and sugar derivatives.

39. The method of claim 2 , wherein the non-ionic solution comprises glycerol at a concentration of 10% to 15%.

40. The kit of claim 21 , wherein the cryopreservative comprises glycerol at a concentration of 10% to 15%.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2010
From: STRATAGENE CALIFORNIA
To: AGILENT TECHNOLOGIES, INC.
Reel/Frame 024630/0870 →
CHANGE OF NAME Recorded Jan 26, 2004
From: STRATAGENE
To: STRATAGENE CALIFORNIA
Reel/Frame 016182/0616 →